2. Academic Validation
  3. Trinucleotide Cap Analogue Bearing a Locked Nucleic Acid Moiety: Synthesis, mRNA Modification, and Translation for Therapeutic Applications

Trinucleotide Cap Analogue Bearing a Locked Nucleic Acid Moiety: Synthesis, mRNA Modification, and Translation for Therapeutic Applications

  • Org Lett. 2021 Jun 4;23(11):4133-4136. doi: 10.1021/acs.orglett.1c01037.
Annamalai Senthilvelan 1,  Tyson Vonderfecht 2,  Muthian Shanmugasundaram 1,  Indra Pal 3,  Jason Potter 2,  Anilkumar R Kore 1
Affiliations

Affiliations

  • 1 Life Sciences Solutions Group, Thermo Fisher Scientific, 2130 Woodward Street, Austin, Texas 78744-1832, United States.
  • 2 Life Sciences Solutions Group, Thermo Fisher Scientific, 5781 Van Allen Way, Carlsbad, California 92008, United States.
  • 3 Life Sciences Solutions Group, Thermo Fisher Scientific, 2202 North Bartlett Avenue, Milwaukee, Wisconsin 53202, United States.
PMID: 34008991 DOI: 10.1021/acs.orglett.1c01037
Abstract

The synthesis of a new trinucleotide cap analogue containing a locked nucleic acid (LNA) moiety such as m7(LNA)G(5')ppp(5')AmpG and its Molecular Biology applications are described. The most appealing feature is that this new cap analogue outperforms the standard trinucleotide cap m7G(5')ppp(5')AmpG and the anti-reverse cap analogue m27,3'-OG(5')ppp(5')G by a factor of 5 in terms of translational efficiency.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z